GGrantIndex
← Leaderboards

Jennifer J Kang-Mieler

Illinois Institute Of Technology

$6,502,963
Attributed
$7,092,352
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,092,352 · 6

By mechanism

R01$6,203,583 · 3
R15$780,769 · 2
R25$108,000 · 1

Top collaborators

Most similar at Illinois Institute Of Technology

Same institution · by research overlap

Others in their field

Top investigators on “Technology

Research focus

TechnologyBlood VesselsDiabetic RetinopathyRetinaRodent ModelScanningBaseImaging ModalityOptical Coherence TomographyHemorrhageVascular PermeabilitiesMicrospheresClinical PracticeSiteVascular Endothelial Growth FactorsFluorescein AngiographyHealthcare SystemsBlood FlowMeasurementImageSuccessSafetyAge Related Macular DegenerationAnimals

Grant awards (21)

Deep Learning-based Diagnosis of Retinopathy of Prematurity$504,847
R01 · FY2025 · EY · contact PI
Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)$441,907
R01 · FY2025 · EY · contact PI
Deep Learning-based Diagnosis of Retinopathy of Prematurity$580,331
R01 · FY2024 · EY · contact PI
Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)$446,347
R01 · FY2024 · EY · contact PI
Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)$452,262
R01 · FY2023 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$257,400
R01 · FY2023 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$561,278
R01 · FY2022 · EY · contact PI
Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)$504,051
R01 · FY2022 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$24,999
R01 · FY2022 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$584,346
R01 · FY2021 · EY · contact PI
Dynamic Tracer Kinetic Model to Detect Preclinical Diabetic Retinopathy (DR)$530,753
R01 · FY2021 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$52,250
R01 · FY2021 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$624,845
R01 · FY2020 · EY · contact PI
Sustained Ocular Drug Delivery System for Anti-VEGF Agents$637,967
R01 · FY2019 · EY · contact PI
Efficacy of the Microsphere-Thermo-Responsive Hydrogel Ocular Drug Delivery System$419,899
R15 · FY2016 · EY · contact PI
BME design challenge of improving surgical safety$21,600
R25 · FY2016 · EB · contact PI
BME design challenge of improving surgical safety$21,600
R25 · FY2015 · EB · contact PI
BME design challenge of improving surgical safety$21,600
R25 · FY2014 · EB · contact PI
BME design challenge of improving surgical safety$21,600
R25 · FY2013 · EB · contact PI
BME design challenge of improving surgical safety$21,600
R25 · FY2012 · EB · contact PI
Biocompatibility of thermo-responsive hydrogel ocular drug delivery system$360,870
R15 · FY2010 · EY · contact PI